PathGen Diagnostik Teknologi develops low-cost molecular diagnostic kits for cancer and other diseases, utilizing advanced techniques in molecular biology to facilitate clinical implementation. The company addresses the high cost of existing diagnostic methods, making essential testing more accessible to healthcare providers and patients.
Funding
Funding not disclosed
EVFounders
Product
Problem
Existing molecular diagnostic methods for cancer and other diseases are often expensive, limiting accessibility for healthcare providers and patients, particularly in lower and middle-income countries. This high cost can hinder timely diagnosis and treatment, leading to poorer patient outcomes.
Solution
PathGen Diagnostik Teknologi develops and commercializes low-cost molecular diagnostic kits to improve the accessibility of essential testing. By leveraging advanced techniques in molecular biology, PathGen aims to facilitate the clinical implementation of diagnostics for cancer and other diseases. Their initial product, BiocoloMelt-Dx, is a PCR-based cancer diagnostic kit specifically designed for colorectal cancer, offering an affordable and comprehensive solution. PathGen's products support the democratization of genomics solutions, enabling wider access to critical diagnostic information.
Target Audience
The primary target audience includes healthcare providers, hospitals, and diagnostic laboratories in lower and middle-income countries seeking affordable and reliable molecular diagnostic solutions, as well as clinical and scientific communities involved in cancer research and diagnostics.
Features
- Development of low-cost molecular diagnostic kits for various diseases, including cancer.
- BiocoloMelt-Dx: A comprehensive and affordable PCR-based diagnostic kit for colorectal cancer.
- Utilizes advanced molecular biology techniques for clinical implementation.
- Focus on democratizing genomics solutions in lower and middle-income countries.
- Compatible with quantitative analysis of High-Resolution Melting PCR.